The 'new age of thrift' will benefit copycat drugs

Nearly $70bn-worth of brand-name drugs will lose their US patent protection between now and 2012, thus paving the way for generic subsititutes costing 30-80% less. Eoin Gleeson examines the generic drugs market, and chooses two of the sector's best bets.

America has been gripped by a new spirit of thrift. After 20 years of frittering away every dollar that came their way, US consumers are now cutting up their credit cards. Consumer spending is falling faster than at any time since World War II. As The Economist announced this week: "A new age of thrift has begun."

This will affect all aspects of American life. Take drugs, for example. Many baby boomers have got used to meeting each day with a cocktail of pharmaceuticals. But with Medicare funds running dry just as the population greys, both patients and the government are in need of a cheap alternative to expensive brand-name drugs.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

Eoin came to MoneyWeek in 2006 having graduated with a MLitt in economics from Trinity College, Dublin. He taught economic history for two years at Trinity, while researching a thesis on how herd behaviour destroys financial markets.